Pyridostigmine Related Published Studies
Well-designed clinical trials related to Pyridostigmine
Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. [2010.11]
Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. [2009.08]
Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. [2009.07]
The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. [2009.03]
A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. [2008.02]
Pyridostigmine, diethyltoluamide, permethrin, and stress: a double-blind, randomized, placebo-controlled trial to assess safety. [2006.10]
Pyridostigmine treatment trial in neurogenic orthostatic hypotension. [2006.04]
Early and late reversal of rocuronium with pyridostigmine during sevoflurane anaesthesia in children. [2004.10]
Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia. [2004.10]
Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement. [2003.12]
The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis. [2003.10]
Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. [2003.09]
Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. [2003.08]
Cardiac function during mental stress: cholinergic modulation with pyridostigmine in healthy subjects. [2003.08]
Physiological and performance effects of pyridostigmine bromide in healthy volunteers: a dose-response study. [2002.07]
Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease. [2002.06]
Side effects of low-dose pyridostigmine bromide are not related to cholinesterase inhibition. [2001.12]
Exercise stress testing in healthy subjects during cholinergic stimulation after a single dose of pyridostigmine. [2001.04]
Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects. [2001.02]
Reduction of QTc interval dispersion. Potential mechanism of cardiac protection of pyridostigmine bromide. [2000.09]
The effect of oral pyridostigmine bromide nerve agent prophylaxis on return of twitch height in persons receiving succinylcholine. [2000.04]
A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. [1999.10.12]
Effects of pyridostigmine and naloxone on the abnormal TSH response to TRH during starvation in humans. [1999.05]
Pyridostigmine cotreatment for controlled ovarian hyperstimulation in low responders undergoing in vitro fertilization-embryo transfer. [1999.04]
Cholinergic stimulation with pyridostigmine, hemodynamic and echocardiographic analysis in healthy subjects. [1999.03]
Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress. [1999.02]
The effect of short-term cortisol changes on growth hormone responses to the pyridostigmine-growth-hormone-releasing-hormone test in healthy adults and patients with suspected growth hormone deficiency. [1998.08]
Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. [1998.03]
Cholinergic enhancement by pyridostigmine increases the insulin response to glucose load in obese patients but not in normal subjects. [1997.12]
Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man. [1997.10]
Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release. [1997.10]
Lack of bioavailability of mebeverine even after pretreatment with pyridostigmine. [1997]
Resting and reflex heart rate responses during cholinergic stimulation with pyridostigmine in humans. [1996.11]
Neuromuscular blocking action of suxamethonium after antagonism of vecuronium by edrophonium, pyridostigmine or neostigmine. [1996.10]
The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome. [1996.09]
Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine. [1995.11]
Combined pyridostigmine-thyrotrophin-releasing hormone test for the evaluation of hypothalamic somatostatinergic activity in healthy normal men. [1995.10]
Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. [1995.02]
Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. [1994.11.15]
Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II Diabetic patients. [1994.07]
Reduced growth hormone response to L-dopa and pyridostigmine in obesity. [1994.07]
Effect of pyridostigmine on the hydrocortisone-mediated decrease of circulating growth hormone levels in acromegaly. [1994.06]
Time dependency of pyridostigmine-induced growth hormone response. [1994.04]
Effect of pyridostigmine bromide on acceleration tolerance and performance. [1994.02]
The effect of pyridostigmine on bronchial hyperreactivity. [1993.06]
[A comparison of the two anticholinergic agents atropine and glycopyrrolate during antagonism of a muscle relaxation with pyridostigmine] [1993]
The late growth hormone rise induced by oral glucose is enhanced by cholinergic stimulation with pyridostigmine in normal subjects. [1992.10]
Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone. [1992.09]
Sex steroid priming effects on growth hormone response to pyridostigmine throughout the menstrual cycle. [1992.07]
Safety of pyridostigmine in hypertensive patients receiving beta blockers. [1992.02.15]
Effects of pyridostigmine on spontaneous and growth hormone-releasing hormone stimulated growth hormone secretion in children on daily glucocorticoid therapy after liver transplantation. [1991.12]
Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients. [1991.11]
Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children. [1991.05]
Effect of pretreatment with oral pyridostigmine on subsequent activity of alcuronium in non-anaesthetized subjects. [1991.03]
Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. [1990.12]
Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome. [1990.08]
Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine. [1990.06]
Heat-exercise performance of pyridostigmine-treated subjects wearing chemical protective clothing. [1990.04]
Effect of pyridostigmine on the exercise-heat response of man. [1990]
Acute effects of oral pyridostigmine on memory and cognitive function in SDAT. [1989.03]
A study of the interaction between oxytetracycline and pyridostigmine. [1988.05]
Growth hormone responses to pyridostigmine in normal adults and in normal and short children. [1987.12]
Neostigmine, pyridostigmine and edrophonium as antagonists of deep pancuronium blockade. [1987.11]
Well-designed clinical trials possibly related to Pyridostigmine
Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small,
randomized, double-blind, placebo-controlled, counterbalanced, crossover trial
assessing daily pain levels. [2013]
Long-term effects of doxazosin, finasteride, and combination therapy on quality
of life in men with benign prostatic hyperplasia. [2013]
Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal
Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical
trial. [2013]
A Multicentre Randomised Trial of Atorvastatin Therapy in Intensive Care Patients
with Severe Sepsis. [2013]
Sodium hyaluronate for the treatment of chronic shoulder pain associated with
glenohumeral osteoarthritis: a multicenter, randomized, double-blind,
placebo-controlled trial. [2013]
Effect of dietary myo-inositol supplementation in pregnancy on the incidence of
maternal gestational diabetes mellitus and fetal outcomes: a randomized
controlled trial. [2013]
Effect of vitamin D supplementation on progression of knee pain and cartilage
volume loss in patients with symptomatic osteoarthritis: a randomized controlled
trial. [2013]
Effect of valsartan on systemic right ventricular function: a double-blind,
randomized, placebo-controlled pilot trial. [2013]
Assessment of cognitive impairments and seizure characteristics in
electroconvulsive therapy with and without sodium valproate in manic patients. [2013]
Zinc and copper supplementation are not cost-effective interventions in the
treatment of acute diarrhea. [2013]
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D
conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster
randomised trial. [2013]
Efficacy and safety of everolimus for subependymal giant cell astrocytomas
associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised,
placebo-controlled phase 3 trial. [2013]
Randomized clinical trial of goal-directed fluid therapy within an enhanced
recovery protocol for elective colectomy. [2013]
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
Periarticular infiltration of 0.25% bupivacaine on top of femoral nerve block and
intrathecal morphine improves quality of pain control after total knee
arthroplasty: a randomized double-blind placebo controlled clinical trial. [2012]
Hyperbaric side effects in a traumatic brain injury randomized clinical trial. [2012]
Efficacy and tolerability of a cream containing AR-GG27® (sorbityl furfural
palmitate) in the treatment of mild/moderate childhood atopic dermatitis
associated with pityriasis alba. A double-blind, placebo-controlled clinical
trial. [2012]
Randomized, double-blind, parallel-controlled clinical trial on correspondence of
prescriptions and traditional Chinese medicine syndrome of ischemic stroke. [2012]
[Meta-analysis of Dengzhanxixin injection treatment for unstable angina
pectoris]. [Article in Chinese] [2012]
Phase II trial of methotrexate in myasthenia gravis. [2012]
Repurposing of yunnan baiyao as an alternative therapy for minor recurrent
aphthous stomatitis. [2012]
Psychogenic nonepileptic seizures: a treatment review. What have we learned since
the beginning of the millennium? [2012]
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With
Type 2 Diabetes and Coronary Artery Disease. [2012]
Randomized controlled trial of interventions for young people at ultra-high risk
of psychosis: twelve-month outcome. [2012]
Current position of phenobarbital in epilepsy and its future. [2012]
The DRD4 Exon III VNTR, Bupropion, and Associations With Prospective Abstinence. [2012]
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results
of two randomized, double-blind, parallel-sequential trials. [2012]
Assessment of the effects of a stannous fluoride dentifrice on gingivitis in a
two-month positive-controlled clinical study. [2012]
The effect of zinc acetate and magnolia bark extract added to chewing gum on
volatile sulfur-containing compounds in the oral cavity. [2012]
Effects of continuous positive airway pressure on neurocognitive function in
obstructive sleep apnea patients: The Apnea Positive Pressure Long-term Efficacy
Study (APPLES). [2012]
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial
of suvorexant. [2012]
Pilot study comparing total intravenous anesthesia to inhalational anesthesia in
endoscopic sinus surgery: novel approach of blood flow quantification. [2012]
Comprehensive self management and routine monitoring in chronic obstructive
pulmonary disease patients in general practice: randomised controlled trial. [2012]
The effect of an osmotic contrast agent on complete meconium evacuation in
preterm infants. [2012]
Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in
patients with ulcerative colitis: a prospective randomized, double blind,
sham-controlled clinical trial. [2012]
Autologous olfactory mucosal cell transplants in clinical spinal cord injury: a
randomized double-blinded trial in a canine translational model. [2012]
Effect of citicoline on functional and cognitive status among patients with
traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). [2012]
Oral L-arginine supplementation in patients with mild arterial hypertension and
its effect on plasma level of asymmetric dimethylarginine, L-citruline,
L-arginine and antioxidant status. [2012]
|
